10-KPeriod: FY2006

GILEAD SCIENCES, INC. Annual Report, Year Ended Dec 31, 2006

Filed February 27, 2007For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) reported strong performance for the fiscal year ending December 31, 2006, driven by significant growth in its HIV product portfolio, particularly Truvada and the newly launched Atripla. Total revenues reached $3.03 billion, a substantial increase from the previous year, fueled by a 43% rise in product sales to $2.59 billion. The company also saw a notable increase in royalty revenue, largely due to Tamiflu sales. Strategic acquisitions of Corus Pharma and Myogen in the respiratory and cardiopulmonary disease areas expanded Gilead's therapeutic focus beyond infectious diseases. The company continues to invest heavily in research and development, with expenses increasing by 38% in 2006 to support its diverse pipeline. Despite challenges such as increasing competition and the adoption of new accounting standards for stock-based compensation, Gilead demonstrated robust financial health and a clear strategy for future growth through both internal development and strategic acquisitions.

Key Highlights

  • 1Total revenues grew 43% to $3.03 billion, driven by a 43% increase in product sales to $2.59 billion.
  • 2HIV product sales increased 52% to $2.13 billion, with Truvada and the newly launched Atripla showing strong growth.
  • 3Acquired Corus Pharma and Myogen, expanding into respiratory and cardiopulmonary disease areas.
  • 4Royalty revenue more than doubled to $416.5 million, primarily from Tamiflu sales.
  • 5Research and Development (R&D) expenses increased 38% to $383.9 million, reflecting investment in pipeline advancement.
  • 6Adopted SFAS 123R, leading to increased stock-based compensation expense, impacting reported net income negatively for the year.
  • 7Cash, cash equivalents, and marketable securities stood at $1.39 billion as of year-end 2006, providing ample liquidity.

Frequently Asked Questions

Gilead's primary revenue drivers in 2006 were its HIV products, particularly Truvada and Viread, which accounted for a significant portion of total sales. The launch of Atripla in July 2006 also contributed positively. Additionally, royalty revenue, largely from Tamiflu, played a substantial role in the company's overall revenue.

The acquisitions of Corus Pharma (respiratory/infectious diseases) and Myogen (cardiopulmonary/cardiovascular disorders) marked a strategic expansion for Gilead beyond its traditional focus on infectious diseases. These acquisitions aimed to diversify the company's pipeline and therapeutic areas, bringing in new product candidates for late-stage development in critical unmet medical needs.

Key risks highlighted include significant revenue reliance on a limited number of products (especially HIV products), intense competition within the pharmaceutical market, potential safety issues with marketed products or pipeline candidates, the complex and lengthy regulatory approval process, reliance on third-party manufacturers and collaborators, and the impact of currency fluctuations and healthcare reimbursement policies on financial performance.

The adoption of SFAS 123R (Share-Based Payment) on January 1, 2006, required Gilead to recognize the fair value of stock-based awards as compensation expense. This resulted in a significant increase in operating expenses, including stock-based compensation, which negatively impacted the reported net income for the year ended December 31, 2006, compared to prior years where such expenses were not fully recognized.